Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- HIVE +3.4%
Other news:
- GGR +9.2% (Castrol to invest up to $50 mln in Gogoro)
- CORZ +8.6% (announces new contract with CoreWeave for delivery of approximately 70 MW of additional infrastructure to host high-performance computing operations)
- ARVN +7.8% (names new CFO)
- HOWL +7.3% (Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma)
- IMMP +5.3% (announces a License Agreement with Cardiff University granting the Company exclusive rights to develop and commercialise anti-LAG-3 small molecules)
- BTAI +5% (Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia) FAAS +4.7% (secures allocation of an initial tranche of 5,120 NVIDIA H200 GPUs)
- CORT +4.6% (announces results from CATALYST study)
- MMLP +4.2% (issues statement on statement on crude oil pipeline spill),
- VIAV +2.9% (Provides Benchmarking and Validation at Spring 2024 O-RAN PlugFest as U.S. NTIA Calls for O-RU Commercialization)
- ADV +2.8% (CEO bought 40000 shares)
- IDYA +2.7% (Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer)
- LOT +2.1% (secures investment from strategic investor)
- IONS +1.8% (announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed)
- PLUG +1.6% (achieved a significant milestone reaching 7.5 gigawatts in global Basic Engineering and Design Package contracts since introducing the offer two years ago)
- DAR +1.1% ( approved the extension for an additional two years of its previously announced share repurchase program and refreshed the amount of the program back up to an aggregate amount of $500.0 million)